| Ferroptosis and cancer prognosis | Lifetime | 27 | HU 1 | 99.45 |
| Gene expression and cancer classification | Lifetime | 63 | HU 1 | 98.93 |
| RNA modifications and cancer | Lifetime | 408 | HU 1 | 99.11 |
| Cancer Genomics and Diagnostics | Lifetime | 336 | HU 1 | 99.36 |
| Cancer-related Molecular Pathways | Lifetime | 255 | HU 1 | 99.02 |
| Cancer-related molecular mechanisms research | Lifetime | 574 | HU 1 | 98.31 |
| Molecular Biology Techniques and Applications | Lifetime | 217 | HU 2 | 98.08 |
| Cancer Cells and Metastasis | Lifetime | 378 | HU 1 | 98.35 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 716 | HU 1 | 98.46 |
| Breast Cancer Treatment Studies | Lifetime | 460 | HU 2 | 98.61 |
| HER2/EGFR in Cancer Research | Lifetime | 397 | HU 1 | 98.30 |
| Bioinformatics and Genomic Networks | Lifetime | 325 | HU 3 | 97.49 |
| Colorectal Cancer Treatments and Studies | Lifetime | 684 | HU 2 | 98.01 |
| Genetic factors in colorectal cancer | Lifetime | 748 | HU 1 | 97.55 |
| Cancer, Lipids, and Metabolism | Lifetime | 921 | HU 3 | 96.85 |
| Cancer-related gene regulation | Lifetime | 886 | HU 1 | 96.10 |
| Advanced Breast Cancer Therapies | Lifetime | 503 | HU 1 | 96.06 |
| Melanoma and MAPK Pathways | Lifetime | 934 | HU 3 | 91.74 |
| Chromatin Remodeling and Cancer | Lifetime | 843 | HU 5 | 84.42 |
| scientometrics and bibliometrics research | Lifetime | 841 | HU 11 | 83.59 |
| Ferroptosis and cancer prognosis | 2021-2025 | 32 | HU 1 | 99.39 |
| Cancer-related Molecular Pathways | 2021-2025 | 9 | HU 1 | 99.16 |
| RNA modifications and cancer | 2021-2025 | 87 | HU 1 | 98.93 |
| Cancer Genomics and Diagnostics | 2021-2025 | 147 | HU 1 | 98.89 |
| Cancer-related gene regulation | 2021-2025 | 36 | HU 1 | 96.74 |
| Epigenetics and DNA Methylation | 2021-2025 | 148 | HU 1 | 96.91 |
| Cancer Cells and Metastasis | 2021-2025 | 74 | HU 1 | 96.59 |
| Genetic factors in colorectal cancer | 2021-2025 | 85 | HU 1 | 97.46 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 84 | HU 1 | 97.15 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 399 | HU 1 | 98.45 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 195 | HU 1 | 97.39 |
| Bioinformatics and Genomic Networks | 2021-2025 | 252 | HU 1 | 90.20 |
| Nutrition, Genetics, and Disease | 2021-2025 | 149 | HU 1 | 88.08 |
| HER2/EGFR in Cancer Research | 2021-2025 | 790 | HU 2 | 87.51 |
| Gene expression and cancer classification | 2021-2025 | 249 | HU 1 | 84.13 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 700 | HU 1 | 83.25 |
| Cell Adhesion Molecules Research | 2021-2025 | 429 | HU 2 | 78.77 |
| Molecular Biology Techniques and Applications | 2021-2025 | 487 | HU 3 | 77.63 |
| Meta-analysis and systematic reviews | 2021-2025 | 394 | HU 2 | 83.69 |
| Melanoma and MAPK Pathways | 2021-2025 | 446 | HU 3 | 80.83 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 972 | HU 3 | 66.25 |
| scientometrics and bibliometrics research | 2021-2025 | 458 | HU 4 | 64.28 |
| Chromatin Remodeling and Cancer | 2021-2025 | 766 | HU 2 | 58.75 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 669 | HU 1 | 55.20 |
| Proteoglycans and glycosaminoglycans research | 2021-2025 | 940 | HU 10 | 49.56 |
| FOXO transcription factor regulation | 2021-2025 | 319 | HU 1 | 46.96 |
| NF-κB Signaling Pathways | 2021-2025 | 682 | HU 1 | 40.60 |
